1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Achiko AG
  6. News
  7. Summary
    ACHI   CH0522213468

ACHIKO AG

(ACHI)
  Report
Delayed Swiss Exchange  -  05/27 11:31:37 am EDT
0.1000 CHF   -1.96%
05/25Achiko Secures $1.3 Million Financing with Strategic Investors Buranto AG and Negma Group
AQ
05/25Achiko AG Appoints Derek Brand to Advisory Board
CI
05/25Achiko AG Secures $1.3 Million Financing with Strategic Investors Buranto AG and Negma Group
CI
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Achiko AG Announces Feature Article on “How We Get Back to Normal” with its AptameX™ Covid-19 Rapid Test Technology

01/18/2022 | 07:31am EDT

ZURICH, Switzerland, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) is pleased to announce a feature article in The Jakarta Post: “How we get back to normal: Restoring Trust and Confidence through Testing with AptameX” which discusses how Achiko is contributing to provide affordable and accurate testing to Indonesia with its Covid-19 saliva-based rapid test AptameX™, which fills the gap between rapid tests and PCR testing.

The article is available at this link: https://www.thejakartapost.com/adv-longform/2022/01/17/how-we-get-back-to-normal-restoring-trust-and-confidence-through-testing-with-aptamex.html and within the News section of Achiko’s web site: https://www.achiko.com/news.

ABOUT ACHIKO AG
Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that puts people first. The company’s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and an application for CE Mark approval in Europe will be submitted in 2022.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameXTM and companion health apps via its digital mobile health technology division, Teman SehatTM. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Headquartered in Zurich, Achiko has offices in Hong Kong, Jakarta, Seoul, and Singapore.

Media contacts:

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

U.S. & Global
Jeanene Timberlake
RooneyPartners
E: jtimberlake@rooneypartners.com
T: +1 646 770 8858

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties, and other factors, which could cause the actual results, financial condition, performance, or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


Primary Logo


© GlobeNewswire 2022
All news about ACHIKO AG
05/25Achiko Secures $1.3 Million Financing with Strategic Investors Buranto AG and Negma Gro..
AQ
05/25Achiko AG Appoints Derek Brand to Advisory Board
CI
05/25Achiko AG Secures $1.3 Million Financing with Strategic Investors Buranto AG and Negma ..
CI
05/25Achiko AG Secures CHF 1.25 million Financing with Strategic Investors Buranto AG and N..
EQ
05/25Achiko AG announced that it expects to receive CHF 1.25 million in funding from Negma G..
CI
05/19Achiko Preliminarily Expects FY21 Loss as Annual Report Delayed by Pandemic, Staffing
MT
05/19Achiko AG Reports Key Unaudited Financial Results for the Year Ended December 31, 2021
AQ
05/19Achiko AG Reports Key Unaudited Financial Results for the Year Ended 31 December 2021
EQ
05/19Achiko AG Reports Key Unaudited Financial Results for the Year Ended 31 December 2021
EQ
05/17Achiko AG Obtains CE Mark for AptameX™ Covid-19 Rapid Test
AQ
More news
Analyst Recommendations on ACHIKO AG
More recommendations
Financials (USD)
Sales 2020 2,81 M - -
Net income 2020 -14,1 M - -
Net Debt 2020 1,57 M - -
P/E ratio 2020 -2,61x
Yield 2020 -
Capitalization 13,9 M 13,9 M -
EV / Sales 2019 -
EV / Sales 2020 14,0x
Nbr of Employees 29
Free-Float 63,9%
Chart ACHIKO AG
Duration : Period :
Achiko AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACHIKO AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Managers and Directors
Steven Goh Chief Executive Officer & Director
Morris S. Berrie President
Adam O’Keeffe Chief Financial Officer
Yao Bian Wu Chairman
Ann Chow Head-Investor Relations
Sector and Competitors
1st jan.Capi. (M$)
ACHIKO AG-42.53%14
INTUIT INC.-34.32%119 172
FIDELITY NATIONAL INFORMATION SERVICES, INC.-3.66%64 224
ADYEN N.V.-34.36%50 340
WORLDLINE-18.69%11 979
KAKAO PAY CORP.-40.40%10 967